Vemurafenib and Trametinib Reduce Expression of CTGF and IL-8 in V600EBRAF Melanoma Cells

Laboratory Investigation - United Kingdom
doi 10.1038/labinvest.2016.140
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Ipilimumab, Vemurafenib, Dabrafenib, and Trametinib: Synergistic Competitors in the Clinical Management of BRAF Mutant Malignant Melanoma

Oncologist
Cancer ResearchMedicineOncology
2013English

Metastatic Melanoma and Vemurafenib: Novel Approaches

Rare Tumors
OncologyHistology
2012English

Synergistic Effects of Vemurafenib and Fingolimod (FTY720) in Vemurafenib‑resistant Melanoma Cell Lines

Molecular Medicine Reports
OncologyGeneticsMolecular BiologyBiochemistryCancer ResearchMolecular Medicine
2018English

Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma

Frontiers in Oncology
Cancer ResearchOncology
2019English

E1A Expression Dysregulates IL-8 Production and Suppresses IL-6 Production by Lung Epithelial Cells

Respiratory Research
PulmonaryRespiratory Medicine
2005English

Improved Overall Survival in Melanoma With Combined Dabrafenib and Trametinib

New England Journal of Medicine
Medicine
2015English

Vemurafenib Potently Induces Endoplasmic Reticulum Stress-Mediated Apoptosis in BRAFV600E Melanoma Cells

Science Signaling
BiochemistryCell BiologyMolecular Biology
2013English

Expression and Function of CD9 in Melanoma Cells

Molecular Carcinogenesis
Cancer ResearchMolecular Biology
2009English

IL-8 and MCP Gene Expression and Production by LPS-Stimulated Human Corneal Stromal Cells

International Journal of Inflammation
AllergyImmunology
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy